320 related articles for article (PubMed ID: 34566963)
21. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer.
Feins S; Kong W; Williams EF; Milone MC; Fraietta JA
Am J Hematol; 2019 May; 94(S1):S3-S9. PubMed ID: 30680780
[TBL] [Abstract][Full Text] [Related]
22. Enhancing Natural Killer Cell Targeting of Pediatric Sarcoma.
Omer N; Nicholls W; Ruegg B; Souza-Fonseca-Guimaraes F; Rossi GR
Front Immunol; 2021; 12():791206. PubMed ID: 34804076
[TBL] [Abstract][Full Text] [Related]
23. Ewing's sarcoma of the hand: localization and treatment.
Euler E; Wilhelm K; Permanetter W; Kreusser T
J Hand Surg Am; 1990 Jul; 15(4):659-62. PubMed ID: 2380532
[TBL] [Abstract][Full Text] [Related]
24. Ewing's sarcoma.
Eggli KD; Quiogue T; Moser RP
Radiol Clin North Am; 1993 Mar; 31(2):325-37. PubMed ID: 8446752
[TBL] [Abstract][Full Text] [Related]
25. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
26. Oncological outcomes of patients with Ewing's sarcoma: is there a difference between skeletal and extra-skeletal Ewing's sarcoma?
Pradhan A; Grimer RJ; Spooner D; Peake D; Carter SR; Tillman RM; Abudu A; Jeys L
J Bone Joint Surg Br; 2011 Apr; 93(4):531-6. PubMed ID: 21464495
[TBL] [Abstract][Full Text] [Related]
27. Ewing's sarcoma. Prognostic factors, disease control, and the reemerging role of surgical treatment.
O'Connor MI; Pritchard DJ
Clin Orthop Relat Res; 1991 Jan; (262):78-87. PubMed ID: 1984935
[TBL] [Abstract][Full Text] [Related]
28. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
30. Non-metastatic Ewing's sarcoma family of tumors of bone in adolescents and adults: prognostic factors and clinical outcome-single institution results.
Oksüz DC; Tural D; Dincbas FÖ; Dervisoglu S; Turna H; Hiz M; Kantarci F; Ceylaner B; Koca S; Mandel NM
Tumori; 2014; 100(4):452-8. PubMed ID: 25296596
[TBL] [Abstract][Full Text] [Related]
31. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
[TBL] [Abstract][Full Text] [Related]
32. Comparison of soft tissue Ewing's sarcoma and peripheral neuroectodermal tumor.
Siebenrock KA; Nascimento AG; Rock MG
Clin Orthop Relat Res; 1996 Aug; (329):288-99. PubMed ID: 8769464
[TBL] [Abstract][Full Text] [Related]
33. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
34. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
35. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997.
Bacci G; Ferrari S; Longhi A; Donati D; De Paolis M; Forni C; Versari M; Setola E; Briccoli A; Barbieri E
Ann Oncol; 2003 Nov; 14(11):1654-9. PubMed ID: 14581274
[TBL] [Abstract][Full Text] [Related]
36. Present trends in treatment of Ewing's sarcoma.
Delépine N; Delépine G; Desbois JC
Biomed Pharmacother; 1990; 44(5):249-56. PubMed ID: 2091807
[TBL] [Abstract][Full Text] [Related]
37. Ewing's sarcoma.
Meyers PA; Levy AS
Curr Treat Options Oncol; 2000 Aug; 1(3):247-57. PubMed ID: 12057167
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications.
Thanindratarn P; Dean DC; Nelson SD; Hornicek FJ; Duan Z
Cancer Treat Rev; 2020 Jan; 82():101934. PubMed ID: 31794912
[TBL] [Abstract][Full Text] [Related]
39. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.
Tanaka M; Yamazaki Y; Kanno Y; Igarashi K; Aisaki K; Kanno J; Nakamura T
J Clin Invest; 2014 Jul; 124(7):3061-74. PubMed ID: 24911143
[TBL] [Abstract][Full Text] [Related]
40. The Ewing's sarcoma family of tumors: Ewing's sarcoma and peripheral primitive neuroectodermal tumor of bone and soft tissue.
Granowetter L; West DC
Cancer Treat Res; 1997; 92():253-308. PubMed ID: 9494764
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
